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Formaldehyde has been previously shown to play a dominant role in promoting synergy between doxorubicin (Dox) and
formaldehyde-releasing butyric acid (BA) prodrugs in killing cancer cells. In this work, we report that these prodrugs also protect
neonatal rat cardiomyocytes and adult mice against toxicity elicited by Dox. In cardiomyocytes treated with Dox, the formaldehyde
releasing prodrugs butyroyloxymethyl diethylphosphate (AN-7) and butyroyloxymethyl butyrate (AN-1), but not the corresponding
acetaldehyde-releasing butyroyloxydiethyl phosphate (AN-88) or butyroyloxyethyl butyrate (AN-11), reduced lactate dehydrogen-
ase leakage, prevented loss of mitochondrial membrane potential (DCm) and attenuated upregulation of the proapoptotic gene Bax.
In Dox-treated mice, AN-7 but not AN-88 attenuated weight-loss and mortality, and increase in serum lactate dehydrogenase. These
findings show that BA prodrugs that release formaldehyde and augment Dox anticancer activity also protect against Dox
cardiotoxicity. Based on these observations, clinical applications of these prodrugs for patients treated with Dox warrant further
investigation.
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Cardiotoxicity is a significant complication of cancer treatment.
The anthracycline doxorubicin (Dox) is one of the most widely
employed anticancer agents whose clinical use is limited by acute
and chronic cardiotoxicity (DeVita et al, 2001). Studies have
shown that heart failure in Dox-treated patients may take place
many years after treatment cessation (Steinherz and Steinherz,
1991). Retrospective analysis of three clinical trials with 630 breast
carcinoma and small-cell lung carcinoma patients indicated that
at a cumulative dose of 550mgm
 2, an estimated 26% of patients
experienced Dox-related congestive heart failure (Swain et al,
2003).
The molecular basis of Dox-induced cardiotoxicity is attributed
to several different molecular events: generation of reactive oxygen
species (ROS), impaired calcium homeostasis and mitochondrial
functions, reduced expression of energy-generating enzymes and
degradation of Dox to its toxic metabolite doxorubicinol
(Mohamed et al, 2000; Minotti et al, 2001). The vulnerability
of the heart to ROS is further intensified by Dox inhibition of
ROS neutralising enzymes (Li et al, 2000). The drug ICRF-187
(dexrazoxane) is the only registered and clinically successful
cardiotoxicity modulator that chelates iron and inhibits formation
of the oxygen-free radicals, yet the controversy about its effect
against cardiotoxicity justifies a search for additional protective
agents (Hofland et al, 2005; Elbl et al, 2006).
We have previously studied a family of acyloxyalkyl ester
prodrugs of histone deacetylase (HDAC) inhibitors having the
general formula Me(CH2)2COOCH(R)OR
1,( R ¼H, Me, Pr, t-Bu;
R
1¼OC-alkyl, and P(O)(OEt)2) that upon metabolic hydrolysis
release acids and aldehydes. These prodrugs possess HDAC
inhibitory activity, anticancer activity and low toxicity (Nudelman
et al, 2005; Rephaeli et al, 2006). The most potent ones
release butyric acid (BA) and formaldehyde upon metabolic
hydrolysis (Nudelman et al, 2005). As anticancer agents they act
in synergy with Dox by increasing the number of Dox–DNA
adducts formed (Cutts et al, 2001; Engel et al, 2006; Swift et al,
2006).
Recent studies have attributed to histone acetylation a crucial
role in regulating both pro- and antihypertrophic pathways in the
heart (Zhang et al, 2002; Antos et al, 2003; Kook et al, 2003).
Histone deacetylase-9 has been shown to act as a signal-responsive
repressor of cardiac hypertrophy (Zhang et al, 2002). Consistent
with this repressive role, mutant mice lacking HDAC9 are
hypersensitive to hypertrophic signals. In contrast, HDAC2 has
been found in a functional complex with the homeobox protein
Hop, which stimulates hypertrophy by blocking an antihyper-
trophic gene programme dependent on serum response factor
(Kook et al, 2003). Histone deacetylase inhibition in vivo and in
vitro antagonised hypertrophic stimulation of myocytes, support-
ing the notion of histone hyperacetylation-dependent signalling of
cardiac hypertrophy (Antos et al, 2003).
In light of the synergistic interaction between BA and
formaldehyde-releasing acyloxyalkyl prodrugs and Dox in killing
cancer cells, we investigated the manner by which they affect
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protect against Dox toxicity in vitro and in vivo. These
observations make the acyloxymethyl ester prodrugs and particu-
larly AN-7, attractive candidate drugs for cancer treatment.
MATERIALS AND METHODS
The study was conducted according to the NIH Laboratory Animal
Care Guidelines approved by the Tel Aviv University Committee
for Animal Experimentation.
Compounds and reagents
The structure and hydrolysis products of the BA prodrugs,
synthesised as described (Nudelman et al, 2001) and used in this
study, are presented in Table 1. For in vitro studies, AN-7 was
dissolved in the indicated growth medium whereas AN-88, AN-1
and AN-11 were dissolved in DMSO and diluted in the growth
medium to the desired concentration. The final DMSO concentra-
tion was p0.1%. Solutions of the prodrugs were handled using
Hamilton syringes and glass vials. For in vivo studies, AN-7 was
dissolved in saline, and AN-88 in soy oil.
Tissue culture media and serum were obtained from Biological
Industries, Beit-Haemek (Israel); Dox hydrochloride, 2mgml
 1
was from Teva (Petach Tikva, Israel), and JC1 (5,50,6,60-tetra-
chloro-1,10,3,30-tetraethylbenzimidazolylcarbocyanine iodide) was
from Alexis (San Diego, CA, USA). All other chemicals used, if not
specifically indicated, were purchased from Sigma, St Louis, MO,
USA.
Antibodies
Primary antibodies for Western blot analysis: rabbit anti-
acetylated H4 (lysine 12) and rabbit anti-histone H3 were from
Cell Signaling (San Diego, CA, USA). Secondary antibodies:
horseradish peroxidase (HRP)-goat anti-rabbit IgG and HRP-goat
antimouse IgG were from Jackson ImmunoResearch (West Grove,
PA, USA).
Cardiomyocyte culture
Neonatal rat ventricular myocytes were isolated and cultured in
collagen-coated culture dishes as described (Shalitin et al, 1996).
Growth medium contained DMEM:Ham’s F12 (1:1), fetal calf
serum (10%) and antibiotics. Treatment was administered to
spontaneously beating cardiomyocytes 48h after plating.
Cytotoxicity evaluation
Cardiomyocytes were seeded in 24-well plates (5 10
5
cells500ml
 1well
 1) and 2 days later were treated as follows: the
prodrugs (Table 1) were added to the culture either alone for 24 or
1h before addition of 2mM Dox. After 5h, the medium containing
Dox was removed and the prodrug-containing medium was added
again for a total exposure time of 24h. Plates were centrifuged
for 5min at 700g, the supernatant was removed and lactate
dehydrogenase (LDH) activity was determined in the growth
medium and in the remaining cell layer.
Lactate dehydrogenase assay
Lactate dehydrogenase activity was used to assess damage induced
by Dox. Measurements of LDH released into the culture medium
or that which remained in the cell layer, were carried out
spectroscopically with CytoTox 96 non-radioactive cytotoxicity
assay (Promega, Madison, WI, USA). Control (100%) was defined
as LDH released from untreated cells. To optimise the assay we
validated that increased LDH in the medium correlated with
decreased LDH activity in the cell layer.
Assessment of changes in mitochondrial membrane
potential (Dwm)
The fluorescent mitochondrial-specific cationic dye JC-1 was used
to assess the status of Dcm in cardiomyocytes after drug
treatment. JC-1 undergoes potential-dependent accumulation in
the mitochondria. Mitochondria with a normal Dcm concentrate
aggregated JC-1 (red fluorescence) and in depolarised mito-
chondria, JC-1 forms monomers (green fluorescence). Rat
neonatal cardiomyocytes were seeded in 24-well plates
(6 10
5cells500ml
 1well
 1) and treated with 2mM Dox for 5h,
100mM AN-7, AN-88, or the combination of Dox with either AN-7
or AN-88. The prodrug was added 1h before the addition of
Dox for 5h. The Dox was washed out and medium containing the
prodrug was added to the cells for an additional 18h. A stock
solution of JC-1 (1mM in DMSO) was added to 40mM HEPES
buffer, pH 7.4, supplemented with 0.65% NaCl and 4.5gl
 1 glucose
at 371C. The final concentration of JC-1 was 10mM and was loaded
into the mitochondria by incubation of the cells for 60min at 371C.
Following the incubation, the cells were washed with HEPES buffer
(500ml) and images of the stained cells were examined under a
fluorescent microscope (IX70; Olympus Tokyo, Japan) using
excitation filter of 330–385nm and barrier filter at 420nm.
Photographs were captured with an Olympus DP50 digital camera
system. Two independent experiments performed in triplicates
were photographed, and the images were analysed by the ImagePro
Plus 5.1 software. The ratio of green to red areas was measured in
46 different fields in each experimental group and the mean7
s.e.m. calculated.
RNA isolation and analysis
Cells were seeded in 60-mm culture dishes treated with drugs, and
total RNA was extracted using guanidinium isothiocyanate as
described (Chomczynski and Sacchi, 1987), quantified spectro-
photometrically and its integrity validated by electrophoresis in
1% agarose gels (Shalitin et al, 1996). A total of 1mg of total RNA
Table 1 Structure and hydrolysis metabolites of the investigated
prodrugs
Prodrug Structure
Hydrolysis products
(no. equivalents)
AN-7
O O
P
O O
OEt Me
OEt
1 Butyric acid
1 Formaldehyde
AN-1
Me O O Me
O O
2 Butyric acid
1 Formaldehyde
AN-88
O O
P
O O
OEt Me
OEt
Me
1 Butyric acid
1 Acetaldehyde
AN-11
Me O O Me
O O Me
2 Butyric acid
1 Acetaldehyde
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swas reverse-transcribed using M-MLVRT(H-) (Promega) and oligo
dT (10mM). For semiquantitative RT–PCR, the resulting cDNA
samples were amplified with the indicated primer pairs under the
corresponding precalibrated conditions specified in Table 2. For
product amplification, we employed the TaKaRa Taq polymerase
(TaKaRa, Shiga, Japan), except for the Bax amplification with
primer pair [I] where the TaqHot (New England Biolabs, Beverly,
MA, USA) was used. The cycling protocol was 30s denaturation at
951C, 30s annealing at the indicated temperature (Table 2), 50s
elongation at 721C. The PCR products were resolved in 2% agarose
gels, visualised by ethidium bromide staining and UV translumi-
nation, and quantified in the VersaDoc Imaging System using
Quantity One Software (Bio-Rad Laboratories, Hercules, CA, USA).
Expression levels were normalised to that of GAPDH mRNA in
each sample, and the fold change in expression was calculated
relative to the untreated control cultures.
Histone acetylation in cardiomyocytes
Cells seeded in 100-mm culture dishes and at 70–80% confluency
were treated with AN-7 (100mM) for 4h. The medium was
discarded and the cells were rinsed with ice-cold PBS and
harvested with a rubber policeman. For histone determination,
cells were lysed in 1ml of lysis buffer (10mM HEPES, pH 7.9,
1.5mM MgCl2,1 0 m M KCl, 0.5mM DTT, 1.5mM phenylmethane-
sulfonyl fluoride) and histones were extracted and subjected to
Western blot analysis as described (Nudelman et al, 2005).
Histone acetylation in vivo
For determination of histone acetylation in vivo, female C57/BL
mice were treated orally with AN-7 at a dose of 100mgkg
 1 for
30min, 5h and 24h. The heart, liver and kidneys were removed,
frozen immediately in liquid nitrogen and kept at  701C. Histones
were purified and subjected to Western blot analysis (Nudelman
et al, 2005; Rephaeli et al, 2006).
Doxorubicin-induced toxicity in vivo
Female C57/BL mice, 6–10 weeks old (Harlan, Rehovot, Israel)
were treated with a single i.p. dose of 20mgkg
 1 Dox and three
times a week p.o. with vehicle, AN-7 (20mgkg
 1) or AN-88
(20mgkg
 1) for 2 weeks. AN-7 and AN-88 were given 1h before
Dox. At the end of the experiment, blood was drawn from the eyes,
allowed to coagulate, centrifuged twice (10min, 778g) and the
collected serum was analysed for LDH with CytoTox 96 non-
radioactive cytotoxicity assay (Promega). Control (100%) was
defined as the LDH activity in untreated mice.
Statistical analysis
Statistical analysis was performed using Excel Office 2000 for
Student’s t-test, linear regression test and w
2 test.
RESULTS
Protection of neonatal cardiomyocytes against
Dox-induced toxicity
The prodrugs listed in Table 1 were examined for their ability to
protect cardiomyocytes from Dox-induced toxicity. Their effect on
LDH release from the myocytes to the growth medium (after 24h
of treatment with Dox) was measured (Figure 1). In preliminary
dose–response experiments, a concentration of 2mM Dox was
found to cause maximal damage while the prodrugs alone, up to
200mM, did not induce damage to the cells (data not shown).
Moreover, the Dox-induced damage was significantly reduced
when co-treated with prodrugs releasing formaldehyde and BA
(AN-7, AN-1). This protective effect was not observed after
treatment with the combination of Dox and analogous prodrugs
that release acetaldehyde and BA (AN-88, AN-11). The results
indicate that formaldehyde plays a central role in protecting the
cardiomyocytes against Dox-induced damage. It is important to
note that the effect of prodrugs that release one equivalent of BA
(AN-7 or AN-88) was similar to that of prodrugs that release two
equivalents of BA (AN-1 or AN-11, respectively), indicating that
the number of BA equivalents released by the prodrugs does not
contribute to the protective activity.
Protection of neonatal cardiomyocytes from Dox-induced
dissipation of mitochondrial membrane potential
The mitochondria play a critical role in cell death in response to
stress signals. Opening of the mitochondrial permeability transi-
tion pore, results in the loss of DCm, a step preceding cell death
(Crow et al, 2004). We examined the effect of treatment with Dox,
AN-7 and AN-88 alone or the combined treatments of AN-7 or
Table 2 Primers and PCR conditions
Gene Primers (50–30)
Product
size
(bp)
Annealing
T( 1C) Cycles
Bax [I] GCCCACCCAGCTCTGAACAGT
CTGCTCGATCCTGGATGAAAC
71 63 32
Bax [II] TGCAGAGGATGATTGCTGAC
GGAGGAAGTCCAGTGTCCAG
207 60 30
GAPDH CCATGGAGAAGGCTGGGG
CAAAGTTGTCATGGATGACC
195 59 20
GAPDH¼glyceraldehyde-3-phosphate dehydrogenase.
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Figure 1 Protection against Dox-induced toxicity in cardiomyocytes.
Cardiomyocytes were seeded in 24-well plates (5 10
5cellswell
 1) and
2 days later treated with (A) 100mM of AN-7 or AN-88, 2mM Dox, the
combinations of 2mM Dox and 100mM AN-7, 2mM Dox and 100mM
AN-88 or none (control); (B) 100mM AN-1 or AN-11, 2mM Dox, the
combinations of 2mM Dox and 100mM AN-1, 2mM Dox and 100mM
AN-11 or none (control). Lactate dehydrogenase activity in the growth
medium was measured after 24h as specified in Materials and Methods.
Data summarise four (A) and three (B) independent experiments.
*Po0.05 vs control,
#Po0.05 vs Dox,
@Po0.05 AN-7þDox vs
AN-88þDox or
@Po0.05 AN-1þDox vs AN-11þDox.
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control cultures were stained dominantly with a spotted red
colour, indicating normal DCm (Figure 2). Two independent
experiments were performed and quantified by the ImagePro Plus
5.1 software analysis. The ratio of green to red areas is
proportional to the extent of reduction in DCm (Figure 2B).
Cultures of myocytes treated with Dox had the highest ratio of
green to red, indicating that the DCm collapsed and the cells were
destined to undergo apoptosis. The myocyte cultures treated with
AN-7 or Dox together with AN-7 were stained in red fluorescence
that was indistinguishable from that of the untreated control
culture, further supporting the protective role of AN-7 against Dox
toxicity. AN-88, however, appeared to have a dual effect. When
given as a single agent it augmented the ratio of green to red
fluorescence suggesting cell damage, although substantially smaller
than the damage caused by Dox. On the other hand, the combined
treatment of Dox and AN-88 had the same effect on DCm as AN-
88 by itself, suggesting a certain degree of protection against Dox-
induced dissipation of DCm and retention of the AN-88 damaging
capacity.
Effect of Dox and the prodrugs on gene expression in
cardiomyocytes
Cardiomyocytes were treated with Dox (2mM), AN-7 and AN-88
(100mM) and their combination and the influence of the different
treatments on expression of Bax, the proapoptotic gene, was
examined by semiquantitative RT–PCR. Figure 3 presents mRNA
levels of expression as detected by the relative intensity of
ethidium bromide staining, quantified and normalised to GAPDH
expression. Doxorubicin caused an increase in Bax expression that
 Untreated Dox
AN-7+Dox
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AN-88
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Figure 2 The effect of AN-7 and Dox on mitochondrial membrane potential in neonatal rat cardiomyocytes. Cardiomyocytes (6 10
5cellswell
 1, 24-
well plates) were grown for 72h and then treated with 2mM Dox for 5h, 100mM AN-7, 100mM AN-88 or the combination as indicated. In the combination,
the prodrug was added 1h before the addition of 2mM Dox for 5h, when Dox was washed out and medium containing 100mM AN-7 or 100mM AN-88 was
added for additional 18h. The cells were stained with 10mM JC-1 for 1h at 371C and photographed at a magnification of  200 (A). The experiment was
repeated twice, each time in triplicate. Four or more random fields were photographed in each well, the area labelled with green and red fluorescence
measured and the ratio of green-to-red fluorescence calculated. The averages for each experimental group and the between-group comparisons were
calculated (B). Mean7s.e.m.; *Po0.05 vs Dox;
#Po0.05 vs AN-88 and AN88þDox.
Protection of the heart against doxorubicin toxicity
A Rephaeli et al
1670
British Journal of Cancer (2007) 96(11), 1667–1674 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swas lowered dramatically when the cells were co-treated with
AN-7. However, after co-treatment of Dox with AN-88, no such
decrease was observed. When cardiomyocytes were exposed to
AN-7 or AN-88 as single agents, the expression of Bax did not
change (Figure 3).
Cardiomyocytes are protected by the elevation of
endogenous formaldehyde
Although all the investigated prodrugs release BA, the protection
of cardiomyocytes against Dox-induced toxicity was exerted only
by those releasing formaldehyde (AN-7, AN-1) and not by the
analogous acetaldehyde-releasing ones (AN-88, AN-11). Since
succinic acid, by inhibition of formaldehyde dehydrogenase (Cinti
et al, 1976), increases the cellular endogenous formaldehyde level,
we examined the ability of succinate to protect cardiomyocytes.
Cells were treated with Dox (2mM), succinic acid (1, 1.5, 2.5mM)
and their combination. Treatment of the cells with succinic acid
alone had no significant effect on LDH released into the culture
media, yet when co-treated with Dox a statistically significant
reduction in Dox toxicity was obtained (Figure 4). This finding
strongly supports the pivotal role of formaldehyde in cardiomyo-
cyte protection.
Histone hyperacetylation
Previously, we have shown that in cancer cells the formaldehyde
and the acetaldehyde releasing acyloxyalkyl-ester prodrugs in-
crease histone acetylation (Nudelman et al, 2005; Rephaeli et al,
2005, 2006). Treatment of cardiomyocytes with 100mM AN-7 for 4h
also increased histone acetylation (Figure 5), indicating that the
released BA was active as an inhibitor of HDAC in this cell type.
When histones were isolated from the heart of mice treated with
AN-7 or AN-1 (100mgkg
 1, p.o.), a transient increase in histone
acetylation peaking at 5h and diminishing after 24h, was observed
(Figure 5).
Effect of Dox treatment as a single agent or in combination
with the prodrugs on C57/BL mice
The increased histone acetylation in the heart suggested that the
prodrugs reached the heart tissue where they released their
metabolites. This observation provided the rationale that the
prodrugs would be active in vivo. In three independent experi-
ments, performed with C57/Bl mice, administration of a single i.p.
dose of 20mgkg
 1 Dox caused a sharp decline in body weight
during the first 7 days (Figure 6A). While mice treated with
vehicle, p.o. AN-7 or p.o. AN-88 (20mgkg
 1) did not lose weight, a
sharp decline in body weight in all the other Dox-treated groups
was evident. This decline in body weight leveled off and even
slightly reversed; nevertheless, it remained noticeably lower than
that of mice not treated with Dox. In six out of the seven
measurements, significant protection against weight-loss was seen
in mice treated with Dox and AN-7. Co-treatment with Dox and
AN-88 caused a similar decline in weight to Dox alone until day 5
when the body weight of the mice treated with AN-88 and Dox
increased compared to those treated with only Dox. Mortality of
the treated animals occurred on days 4–9 following Dox treatment
and the subsequent increase in body weight may be attributed
mainly to the death of the lowest-weighing mice in the group. In
the Dox-treated group 45% of the mice died, while in the combined
treatments of Dox with AN-7 or AN-88, 33 and 40% mortality
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Figure 3 Effect of Dox and prodrugs on Bax expression in
cardiomyocytes. Cardiomyocytes (6 10
6) were seeded in 60-mm dishes
and treated with 100mM AN-7 or 100mM AN-88 or 2mM Dox or the
combination of Dox with the prodrugs as in Figure 1. Total RNA was
isolated after 24h of treatment and processed for semiquantitative RT–
PCR analysis of Bax mRNA level and normalisation to the GAPDH mRNA
level. (A) A representative gel of RT–PCR products. The variation within
the duplicate of Dox treatment is caused by uneven loading as can be seen
from the GAPDH that serves as a loading control. The ratio of Bax mRNA
to GAPDH mRNA corrects for it. (B) A bar graph summarising the results
of two independent experiments performed in duplicate. *Po0.05 vs the
untreated control;
#Po0.05 vs Dox.
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Figure 5 AN-7 induces histone hyperacetylation in vitro and in vivo.
(A) In vitro acetylation in cardiomyocytes treated with AN-7 (100mM) for
4h. The extracted histones were loaded 40mgproteinlane
 1.( B) Time
course of histone acetylation in the heart of mice treated with 100 mgkg
 1
AN-7 or AN-1 for the indicated duration (h). Histones were loaded
20mgproteinlane
 1. The protein samples were resolved on 15% SDS gels
and subjected to Western blot analysis using the anti-acetylated H4 (lysine
12) and the anti H3 (as a loading control).
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Figure 4 Succinate reduces Dox-induced damage in cultured cardio-
myocytes. Cardiomyocytes (5 10
5cellswell
 1) were seeded in 24-well
plates and treated with succinate (1, 1.5, 2mM), Dox (2mM) and their
combination. Lactate dehydrogenase activity in the growth medium was
measured after 24h as specified in Materials and Methods. Data summarise
four independent experiments performed in triplicate. *Po0.05 vs control;
#Po0.05 vs Dox.
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soccurred, respectively. When the mice were co-treated with AN-7
or AN-88 in addition to Dox, a lower percentage of mortality was
noted. Although the overall decline in mortality in AN-7 and Dox
cotreated mice was not statistically significant (w
2 test P¼0.18,
compared to treatment with Dox alone), in two of the three
experiments, substantial protection by AN-7 was found (w
2 test
P¼0.003 and P¼0.06 compared to Dox treatment). In the AN-88
and Dox cotreated groups, we did not observe significant
protection compared to treatment with Dox alone. On termination
of the experiments, blood was collected from representative
surviving animals of each group and serum LDH activity was
assessed. Over 70% increase in LDH activity was detected in the
Dox, compared to the vehicle, treated group. While co-treatment
of the mice with Dox and AN-7 prevented the rise in serum LDH,
co-treatment with AN-88 did not (Figure 6B). These results are
consistent with the weight-loss and the in vitro data. Since elevated
LDH in serum indicates damage to organs in general and to the
heart in particular, taken together with the weight-loss and the in
vitro data, it implies that AN-7 protected against Dox toxicity in
vitro and in vivo.
DISCUSSION
Previously, we have reported that acyloxymethyl butyrate prodrugs
possess anticancer activity and low toxicity, augmenting Dox
toxicity toward cancer cells (Engel et al, 2006; Rephaeli et al, 2006).
In this study we show, in primary cultures of cardiac myocytes
and in C57/Bl mice, that these same prodrugs (AN-7 or AN-1)
affect myocytes and animals in an opposite manner, namely,
protecting them against Dox toxicity.
The effect of treatment with Dox and the prodrugs was tested
initially on primary cultures of neonatal rat cardiac myocytes
(Table 1). In reproducible experiments, only those prodrugs that
release formaldehyde (AN-1 and AN-7) were effective in reducing
the Dox damage as evident by the increased LDH leakage to the
growth medium. The tested compounds encompassed two pairs
(AN-7, AN-88 and AN-1, AN-11) that have the same chemical
composition except that upon intracellular hydrolysis the former
compound in each pair releases formaldehyde and the latter
acetaldehyde (Table 1). From these data, it can be deduced that
formaldehyde released together with BA endows cardiomyocyte
protection against Dox, whereas acetaldehyde released together
with BA does not. The possibility that formaldehyde alone endows
protection or that acetaldehyde causes toxicity cannot be excluded.
Succinic acid is known to increase the intracellular level of
formaldehyde by inhibiting its oxidation to formic acid (Cinti et al,
1976; Kalasz, 2003). The observations that treatment of cells with
acyloxymethyl esters results in measurable increase of formalde-
hyde concentration in the cell extract (Nudelman et al, 2005), and
that treatment of the cardiomyocytes with succinic acid imparted
protection (Figure 4), support the notion that formaldehyde
participates in the protection activity. Taken together, it can be
deduced that protection concurs with increased cellular formalde-
hyde. Along the same line, Burkhart et al (2006) have shown that a
Dox-formaldehyde conjugate inhibited the growth of cancer cells
better than that of cardiomyocytes while Dox displayed the
opposite specificity.
The possibility that acetaldehyde harms cardiomyocytes was
investigated in the context of alcohol-induced damage to the heart.
It was suggested that acetaldehyde impairs cardiac function by
promoting lipid peroxidation and oxidative damage (Aberle and
Ren, 2003). However, in the LDH assay under the conditions
employed, the acetaldehyde releasing prodrug AN-88, as a single
agent and in combination with Dox, did not offer either toxicity or
protection to the cardiomyocytes.
While the level of released LDH is indicative of plasma
membrane permeabilisation, dissipation of mitochondrial mem-
brane potential signifies that the cardiomyocytes undergo apop-
tosis (Crow et al, 2004; Gao et al, 2006). The changes in Dcm
evaluated by the JC-1 assay showed that treatment with Dox
abolished DCm while AN-7 had no effect and the combination of
both prevented the dissipation. This is in agreement with the
finding described above that AN-7 protects cardiomyocytes from
Dox-induced leakage of cellular LDH. Unlike AN-7, AN-88 as a
single agent caused dissipation of DCm although to a lower extent
than Dox. In the combination of AN-88 and Dox, the dissipation of
DCm was lower than Dox alone but similar to AN-88 as single
agent. This implies that AN-88 has dual effect: on one hand, it
causes damage to the cells and on the other, it attenuates Dox
damage to the myocytes. With our current data, the identity of the
protective or deleterious moiety cannot be resolved. In the LDH
assay, the harmful effect of AN-88 on cardiomyocytes was not
detected, possibly owing to the greater sensitivity of the membrane
potential assay compared to the LDH leakage assay.
In addition to the reduction of DCm, the observation that the
expression of the proapoptotic gene Bax was upregulated by
Dox and attenuated in the combined treatment of AN-7 and Dox,
supports the ability of AN-7 to protect cardiomyocytes. While
AN-7 and AN-88, as single agents, had no effect on Bax expression,
AN-88 in combination with Dox did not moderate the Dox-
enhanced Bax expression. The above indicates that AN-7 is
superior to AN-88 not only as an anticancer agent (Nudelman et al,
2001), but also as a cardioprotective compound in vitro.
Potential clinical use of the protective effect of formaldehyde
releasing prodrugs was tested in the frequently used Dox-induced
toxicity mice model (Li et al, 2006; Lien et al, 2006)
. Three
parameters confirmed the protective effects of AN-7 against Dox-
induced toxicity: abolition of Dox-induced increase in the level of
serum LDH, attenuation of Dox-induced loss in body weight and
reduced mortality. Comparison between the in vivo effect of the
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Figure 6 The effect of Dox and Dox combined with prodrugs on the
body weight and serum LDH. Female C57/Bl mice were treated: once
with: Dox 20mgkg
 1 (n¼51), i.p.; AN-7 20mgkg
 1 (n¼21), AN-88
20mgkg
 1 (n¼11), vehicle (n¼23) and the combination of AN-7þDox
(n¼49) and AN-88þDox (n¼25), p.o., three times a week. (A) Body
weight registration during 17 days. *Po0.05, AN-7þDox vs Dox. (B)
Serum LDH (percent of the control) measured at termination of the
experiment. *Po0.05 vs control;
#Po0.05 vs Dox.
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scombination of AN7 and Dox to that of AN-88 and Dox, further
strengthens data obtained in vitro indicating that the formalde-
hyde released from AN-7 plays a major role in the protective effect.
Histone acetylation seen in myocytes was also observed in hearts
of mice treated with AN-7, indicating that the prodrug reached the
heart and, as found in the myocytes, underwent metabolic
hydrolysis in the heart (Figure 5). Unlike in vitro, where the
protection is clearly of cardiomyocytes, in vivo the whole organism
was targeted and the parameters measured were not restricted to
the heart. Therefore, the prodrug-induced protection in the mice
may involve other organs besides the heart and that will be subject
to future study.
The molecular basis of AN-7 protection against Dox-induced
cardiotoxicity could be explained by a number of different
molecular mechanisms such as the protection of mitochondrial
functions or reduced degradation of Dox to its toxic metabolite
doxorubicinol (Mohamed et al, 2000; Minotti et al, 2001).
Additional known damaging effects of Dox are the generation of
ROS as well as the inhibition of the ROS detoxifying enzyme,
glutathione peroxidase (Li et al, 2000). We postulate that cellular
metabolic hydrolysis of the prodrugs results in the release of an
HDAC inhibitory molecule (BA) and formaldehyde. The latter
readily reacts with Dox to form a Dox-N¼CH2 intermediate.
Concurrently, the BA inhibits HDAC resulting in histone
hyperacetylation and chromatin relaxation. This leads to greater
accessibility of Dox-N¼CH2 to the amino group on the guanine in
GpC DNA sequences resulting in Dox-NH-CH2-NH-DNA (Dox–
DNA adduct) formation (Cutts et al, 2005). The formed adducts
sequester Dox to the nucleus and mitochondria reducing Dox
availability to cytoplasmic degradation enzymes and redox-cycling
that generate ROS. As a result, the adverse effects of the free
cytoplasmic Dox are reduced.
Moreover, because of the intrinsic low toxicity of the prodrugs,
their synergy with Dox would necessitate even lower doses of the
Dox for cancer cell killing and will further reduce cardiotoxicity.
In contrast to the proliferating cancer cells, the mature
cardiomyocytes do not divide, and consequently should be less
debilitated by Dox–DNA adduct formation. In an unpublished
preliminary study, a substantial increase in Dox–DNA adduct
formation was detected by Southern hybridisation in the heart and
muscle tissues of mice treated with the combination of Dox
(15mgkg
 1) and formaldehyde releasing prodrug (200mgkg
 1).
Adduct formation was not detected in these tissues of mice treated
with Dox only. This initial observation supports our working
hypothesis that the formation of Dox–DNA adducts diminishes
Dox-induced damage to cardiomyocytes.
Our findings that AN-7 protects cardiomyocytes against damage
caused by Dox and attenuates the Dox-induced morbidity in mice,
is in contrast to our previously described synergism of the same
drug combination in killing cancer cells (Engel et al, 2006;
Rephaeli et al, 2006). The observations that a single molecule
displays opposing biological roles, toward cancer vs normal
myocardial cells, demonstrate diversity of activity tailored to
particular cell types or tissues that is most desirable for
antineoplastic agent and further support the potential AN-7 for
cancer treatment. The molecular pathways underlying the
cell-type-specific response are currently investigated by us.
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